NCT06329687
Terminated
Phase 4
A Phase 4, Single-Center, Open-Label Study Evaluating the Safety of the Tyrvaya Nasal Pump
Overview
- Phase
- Phase 4
- Intervention
- Tyrvaya Nasal Pump
- Conditions
- Dry Eye
- Sponsor
- Oyster Point Pharma, Inc.
- Enrollment
- 5
- Locations
- 1
- Primary Endpoint
- Number of Participants With Adverse Events
- Status
- Terminated
- Last Updated
- last year
Overview
Brief Summary
The objective of this study is to determine the safety of the Tyrvaya nasal pump.
Detailed Description
The study is testing the hypothesis that the use of the Tyrvaya nasal pump with silicone lubricant does not introduce any additional safety concerns as compared to the safety of the Tyrvaya nasal pump without the additional silicone lubricant.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Be at least 18 years of age
- •Have provided verbal and written informed consent
- •Willing to comply with all study related visits and procedures
Exclusion Criteria
- •Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to Visit 1.
Arms & Interventions
Nasal Pump
Tyrvaya nasal pump with additional silicone lubricant
Intervention: Tyrvaya Nasal Pump
Outcomes
Primary Outcomes
Number of Participants With Adverse Events
Time Frame: 7 days
Number of Participants with Adverse Events with the nasal pump with additional silicone lubricant
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
Evaluation of a New Thermostable Formulation of FLOLAN in Japanese SubjectsCardiovascular DiseaseNCT02705807GlaxoSmithKline10
Completed
Phase 4
A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic SettingMultiple SclerosisNCT03589105Hoffmann-La Roche423
Recruiting
Not Applicable
A Phase 2/3,PSMA-T4, Prostate CancerProstate CancerNCT05847166NCBJ Polatom: Narodowe Centrum Badań Jądrowych Polatom80
Recruiting
Phase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene TherapyMuscular Atrophy, SpinalNCT05861999Hoffmann-La Roche28
Recruiting
Phase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene TherapyMuscular Atrophy, SpinalNCT05861986Hoffmann-La Roche28